Differential influence of p38 mitogen activated protein kinase (MAPK) inhibition on acute phase protein synthesis in human hepatoma cell lines

Annals of the Rheumatic Diseases

Volumn 65, Issue 7, 2006, Pages 929-935

  Westra, J ^a   Bijzet, J ^a   Doornbos Van Der Meer, B ^a   Van Rijswijk, M H ^a   Limburg, P C ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4 FLUOROPHENYL) 1 (3 PHENYLPROPYL) 5 (4 PYRIDINYL) 1H IMIDAZOL 2 YL] 3 BUTYN 1 OL; ACUTE PHASE PROTEIN; C REACTIVE PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; JANUS KINASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; SERUM AMYLOID A; STAT PROTEIN; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; FIBRINOGEN SYNTHESIS; HEPATOMA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PROTEIN SYNTHESIS INHIBITION;

ACUTE-PHASE PROTEINS; ANALYSIS OF VARIANCE; BLOTTING, WESTERN; C-REACTIVE PROTEIN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; COMPLEMENT C3; FIBRINOGEN; HUMANS; IMIDAZOLES; IMMUNIZATION; INTERLEUKIN-1; LIVER NEOPLASMS; MAP KINASE SIGNALING SYSTEM; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SERUM AMYLOID A PROTEIN; STAT3 TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33745700456     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2005.043232     Document Type: Article

References (27)

1. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16.
2. Baumann H, Gauldie J. The acute phase response, Immunol Today 1994;15:74-80.
3. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-54.
4. van Leeuwen MA, van Rijswijk MH, Sluiter WJ, van Riel PL, Kuper IH, van de Putte LB, et al. Individual relationship between progression of radiological damage and the acute phase response in early rheumatoid arthritis. Towards development of a decision support system. J Rheumatol 1997;24:20-7.
5. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003;374:1-20.
6. Ivashkiv LB, Hu X. The JAK/STAT pathway in rheumatoid arthritisipathogenic or protective? Arthritis Rheum 2003;48:2092-6.
7. Egan PJ, Lawlor KE, Alexander WS, Wicks IP. Suppressor of cytokine signaling-1 regulates acute inflammatory arthritis and T cell activation. J Clin Invest 2003;111:915-24.
8. Lejeune D, Dumoutier L, Constantinescu S, Kruijer W, Schuringa JJ, Renauld JC. Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10. J Biol Chem 2002;277:33676-82.
9. Ahmed ST, Mayer A, Ji JD, Ivashkiv LB. Inhibition of IL-6 signaling by a p38-dependent pathway occurs in the absence of new protein synthesis. J Leukoc Biol 2002;72:154-62.
10. Zauberman A, Zipori D, Krupsky M, Ben Levy R. Stress activated protein kinase p38 is involved in IL-6 induced transcriptional activation of STAT3. Oncogene 1999;18:3886-93.
11. Kumar S, Boehm J, Lee JC. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2003;2:717-26.
12. Wadsworth SA, Cavender DE, Beers SA, Lalan P, Schafer PH, Malloy EA, ei al. RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. J Pharmacol Exp Ther 1999;291:680-7.
13. Westra J, Doornbos-Van Der Meer B, de Boer P, van Leeuwen MA, van Rijswijk MH, Limburg PC. Strong inhibition of TNF-alpha production and inhibition of IL-8 and COX-2 mRNA expression in monocyte-derived macrophages by RWJ 67657, a p38 mitogen-activated protein kinase (MAPK) inhibitor. Arthritis Res Ther 2004;6:R384-92.
14. Nikas SN, Drosos AA. SCIO-469 Scios Inc. Curr Opin Investig Drugs 2004;5:1205-12.
15. Gervois P, Vu-Dac N, Kleemann R, Kockx M, Dubois G, Laine B, et al. Negative regulation of human fibrinogen gene expression by peroxisome proliferator-activated receptor alpha agonists via inhibition of CCAAT box/enhancer-binding protein beta. J Biol Chem 2001;276:33471-7.
16. Hazenberg BP, Limburg PC, Bijzet J, van Rijswijk MH. A quantitative method for detecting deposits of amyloid A protein in aspirated fat tissue of patients with arthritis. Ann Rheum Dis 1999;58:96-102.
17. Nishimoto N, Yoshizaki K, Miyasctka N, Yamamoto K, Kawai S, Takeuchi T, et al. I. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial, Arthritis Rheum 2004;50:1761-9.
18. Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2003;2:473-88.
19. Lindqvist E, Eberhardt K, Bendtzen K, Heinegard D, Saxne T. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 2005;64:196-201.
20. Kleemann R, Gervois PP, Verschuren L, Staels B, Princen HM, Kooistra T. Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation, Blood 2003;101:545-51.
21. Smith JW, McDonald TL. Production of serum amyloid A and C-reactive protein by HepG2 cells stimulated with combinations of cytokines or monocyte conditioned media: the effects of prednisolone. Clin Exp Immunol 1992;90:293-9.
22. Parasrampuria DA, de Boer P, Desai-Krieger D, Chow AT, Jones CR. Single-dose pharmacokinetics and pharmacodynamics of RWJ 67657, a specific p38 mitogen-activated protein kinase inhibitors first-in-human study. J Clin Pharmacol 2003;43:406-13.
23. Hagihara K, Nishikawa T, Isobe T, Song J, Sugamata Y, Yoshizaki K. IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system. Biochem Biophys Res Commun 2004;314:363-9.
24. Shen X, Tian Z, Holtzman MJ, Gao B. Cross-talk between interleukin 1 beta (IL-1beta) and IL-6 signalling pathways:IL-1beta selectively inhibits IL-6-activated signal transducer and activator of transcription factor 1 (STAT1) by a proteasome-dependent mechanism. Biochem J 2000;352(Pt 3):913-19.
25. Steel DM, Whitehead AS. The major acute phase reactants:C-reactive protein, serum amyloid P component and serum amyloid A protein. Immunol Today 1994;15:81-8.
26. Cunnane G, Grehan S, Geoghegan S, McCormack C, Shields D, Whitehead AS, et al. Serum amyloid A in the assessment of early inflammatory arthritis. J Rheumatol 2000;27:58-63.
27. Rau B, Steinbach G, Baumgart K, Gansauge F, Grunert A, Beger HG. Serum amyloid A versus C-reactive protein in acute pancreatitis: clinical value of an alternative acute-phase reactant. Crit Care Med 2000;28:736-42.